Skip to content
lifestyle.californiaconsumerbanking.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Alzheimer’s Drug Discovery Foundation
FDA Clearance of C2N Diagnostics’ PrecivityAD2 Blood Test Advances Precision Medicine for Alzheimer’s, Building on Groundwork Laid by Early ADDF Investment
August 20, 2026
CURE ALZHEIMER’S FUND APPOINTS NEW EXECUTIVE VICE PRESIDENT OF MARKETING AND COMMUNICATIONS
August 20, 2026
Diranersen Results at AAIC Provide First Evidence That Targeting Tau May Slow Cognitive Decline, Signaling Momentum Toward Addressing the Full Pathobiology of Alzheimer’s
July 14, 2026
ADDF Statement: FDA Approval of Subcutaneous Starting Dose for Leqembi Advances Alzheimer’s Care Toward Combination Therapy Future
July 13, 2026
The Alzheimer’s Drug Discovery Foundation and The Michael J. Fox Foundation Launch $5 Million Partnership to Target Key Co-Pathologies Driving Alzheimer’s and Parkinson’s
July 13, 2026
New Alzheimer’s & Dementia Paper Highlights SpeechDx’s Role in Advancing AI-Driven Tools for Earlier Alzheimer’s Detection and Risk Assessment
June 22, 2026
Alzheimer’s Drug Discovery Foundation Begins Search for New Chief Science Officer as Co-Founder Dr. Howard Fillit Transitions to Emeritus Role
June 18, 2026
Clinical Trials on Alzheimer’s Disease Conference and Alzheimer’s Drug Discovery Foundation Partner to Advance Emerging Biotech Innovation at CTAD 2026
June 16, 2026
The ADDF Highlights Encouraging Progress Toward Targeting Multiple Alzheimer’s Pathologies in Biogen’s Phase 2 Tau Study
May 14, 2026
CURE ALZHEIMER’S FUND PRESENTS THE 2026 JEFFREY L. MORBY PRIZE FOR EXCEPTIONAL RESEARCH
May 8, 2026
1
2
Next Page
→